Novartis Investigative Site

Woodville, South Australia 5011

0 studies enrolling now · 8 studies all time

What they study most

HER-2 Positive Breast Cancer, Locally Advanced Metastatic BRAF Mutant Melanoma, Melanoma, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Relapsing Forms of Multiple Sclerosis, Renal Cell Carcinoma, Sjögren Syndrome

Studies at this site

• A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome — Stopped early
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma — Completed
• A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer — Completed
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma — Completed
• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. — Stopped early
• Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma — Completed
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib — Completed